SCHEMBL20545196

SCHEMBL20545196

CCOC(=O)c1ccc(CCCSc2ccccc2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.55
HDAC1 Q13547 1/20 0.50
KMT2A Q03164 3/20 0.49
MEN1 O00255 2/20 0.49
PTPN1 P18031 1/20 0.48
ALDH1A1 P00352 3/20 0.47
GAA P10253 2/20 0.47
MAPT P10636 1/20 0.47
ALOX12 P18054 1/20 0.47
PLA2G2A P14555 1/20 0.47
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
ESR1 P03372 2/20 0.47
ESR2 Q92731 2/20 0.47
PLA2G4B P0C869 2/20 0.46
CA12 O43570 1/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
CA7 P43166 1/20 0.46
CA9 Q16790 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25340300 0.84 SMN1; SMN2 (0.69) SMN1; SMN2KMT2AMEN1PTPN1ALDH1A1
SCHEMBL11602353 0.80 TDP1 (0.58) SMN1; SMN2KMT2AMEN1GAAMAPT
SCHEMBL5117533 0.79 LMNA (0.53) SMN1; SMN2KMT2AMEN1PTPN1MAPT
SCHEMBL6258642 0.79 SMN1; SMN2 (0.49) SMN1; SMN2KMT2AMEN1PTPN1ALDH1A1
SCHEMBL570747 0.78 ESR1 (0.59) SMN1; SMN2ALDH1A1ESR1ESR2CA12
SCHEMBL9794850 0.77 CA1 (0.51) SMN1; SMN2KMT2AMEN1ALDH1A1MAPT
SCHEMBL9038966 0.77 CA12 (0.51) SMN1; SMN2KMT2AMEN1ALDH1A1MAPT
SCHEMBL12199135 0.77 CA1 (0.68) SMN1; SMN2KMT2AMEN1PTPN1ALDH1A1
SCHEMBL10586967 0.77 HSD17B10 (0.63) SMN1; SMN2HDAC1KMT2AMEN1PTPN1
SCHEMBL4373451 0.77 KMT2A (0.61) SMN1; SMN2KMT2AMEN1MAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12478594-B2 Methods of treatment of kidney injury associated with infection or trauma University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2025-11-25 US disclosed
US-20220226266-A1 Methods of Treatment of Kidney Injury Associated with Infection or Trauma NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2022-07-21 US disclosed
WO-2020240524-A2 METHODS OF TREATMENT OF KIDNEY INJURY ASSOCIATED WITH INFECTION OR TRAUMA UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2020-12-03 WO disclosed
US-20200207691-A1 Class of HDAC Inhibitors Expands the Renal Progenitor Cells Population and Improves the Rate of Recovery from Acute Kidney Injury UNIVERSITY OF PITTSBURGH - OF T 2020-07-02 US disclosed
US-20200207691-A1 Class of HDAC Inhibitors Expands the Renal Progenitor Cells Population and Improves the Rate of Recovery from Acute Kidney Injury UNIVERSITY OF PITTSBURGH - OF T 2020-07-02 US disclosed
US-10626071-B2 Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2020-04-21 US disclosed
US-10626071-B2 Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2020-04-21 US disclosed
US-10160705-B2 Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2018-12-25 US disclosed
US-20180312455-A1 Class of HDAC Inhibitors Expands the Renal Progenitor Cells Population and Improves the Rate of Recovery from Acute Kidney Injury UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2018-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10160705-B2 Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury HDAC1, HDAC9, HDAC11 SMN1; SMN2 3241/4885HDAC1 1/4885KMT2A 41/4885
US-20220226266-A1 Methods of Treatment of Kidney Injury Associated with Infection or Trauma MMP8, PLAU, KLKB1 SMN1; SMN2 4808/4885HDAC1 1068/4885KMT2A 3363/4885
US-10626071-B2 Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury HDAC1, HDAC9, HDAC11 SMN1; SMN2 3241/4885HDAC1 1/4885KMT2A 41/4885
US-20180312455-A1 Class of HDAC Inhibitors Expands the Renal Progenitor Cells Population and Improves the Rate of Recovery from Acute Kidney Injury HDAC1, HDAC9, HDAC11 SMN1; SMN2 3241/4885HDAC1 1/4885KMT2A 41/4885
US-20200207691-A1 Class of HDAC Inhibitors Expands the Renal Progenitor Cells Population and Improves the Rate of Recovery from Acute Kidney Injury HDAC1, HDAC9, HDAC11 SMN1; SMN2 3241/4885HDAC1 1/4885KMT2A 41/4885
US-12478594-B2 Methods of treatment of kidney injury associated with infection or trauma HDAC1, HDAC2, HDAC4 SMN1; SMN2 4839/4885HDAC1 1/4885KMT2A 51/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.